Originally published November 6, 2007 at 12:00 AM | Page modified November 6, 2007 at 2:01 AM
Seattle Genetics therapy trial encouraging
Seattle Genetics said Monday that its cancer therapy SGN-35 showed encouraging results in an early-stage clinical trial, boosting the strength...
Seattle Times business reporter
Seattle Genetics said Monday that its cancer therapy SGN-35 showed encouraging results in an early-stage clinical trial, boosting the strength of its pipeline of product candidates.
The data could make the firm more attractive to prospective partners or buyers, an analyst said.
The Bothell-based company said that more than 75 percent of enrolled patients, most of them with relapsed Hodgkin's disease, saw their tumors shrink after treatment.
The study is still in progress, but the results were so promising that Seattle Genetics decided to release an interim report, said Chief Executive Clay Siegall.
"We felt it was important enough data to release the information to the medical community," Siegall said.
This is the second Seattle Genetics product candidate to have clinical data supporting its claims. Early results for the company's lead product, a blood-cancer therapy known as SGN-40, drew Genentech in January into a development partnership potentially worth hundreds of millions. Seattle Genetics plans to announce early-stage clinical results for a third anti-cancer product, SGN-33, next month.
"We're transitioning from a company with one product with one strong clinical proof concept to a company that has three products," Siegall said.
The data could pave the way for a lucrative partnership similar to the Genentech deal, or an attract acquisition offer from Big Pharma or a large biotech company, said David Miller, a Seattle-based analyst with Biotech Stock Research.
SGN-35's experimental performance adds luster to Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology, which the company employs in two other experimental therapies, currently at the preclinical stage. This method enables antibodies that target cancer cells to carry oncology drugs directly to them.
"The speed with which Seattle Genetics gets acquired by another [company] is related to the quality of the data for SGN-35," said Miller. "The quality of this data was pretty good."
The results, however, did not give Seattle Genetics' stock a boost. Shares dropped 3.14 percent Monday to $10.49.
Seattle Genetics is not in a hurry to partner up with Big Pharma on this product, but it doesn't rule out that option either, Siegall said.
![]()
"The longer you hold these types of products the more value they get," he said. "But if the deal is strong enough with the right company and the right setup, yes, we'd consider it."
Ángel González: 206-515-5644
Copyright © 2007 The Seattle Times Company
UPDATE - 03:29 AM
Bill Clinton meets with Senate Dems on health care
Credit-card holders to pay the price for banks' struggles
Kraft's offer for sweets giant Cadbury turns bitter after rejection
Fewer fliers expected over holidays
Big bonuses coming at 3 big banks

Ken Auletta talks about "Googled"
Ken Auletta talks about Google with Brier Dudley at the Seattle Central Library.
nwjobs

Post a comment

Michelle Goodman blogs about work/life balance.
How to tell your office you're gravely ill
Post a comment
nwautos

Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment
- 'Missing' SeaTac man found with new name, in new state
- Police: DNA from officer's slaying matches suspect
- Prosecutors consider charges against suspect in police shooting
- Three more fires ignite in Greenwood
- Steve Kelley | Hasselbeck gives Seahawks' sagging season a stay of execution
- Plans call for Triangle to become West Seattle gateway
- Bill Clinton meets with Senate Dems on health care
- Trucker dies as big-rig plummets off SF bridge
- McGinn next Seattle mayor; Mallahan concedes as vote gap widens
- Washington coordinator Nick Holt says his Huskies defense is improving
- Prosecutors prepare charges against suspect in police shooting
257 - House health bill unacceptable to many in Senate
246 - Pelosi tours Seattle's Swedish after health-care vote
171 - Prosecutors prepare charges against suspect in police shooting
143 - Alleged shooter tied to mosque of 9/11 hijackers
135 - Obama puts heat on Senate to speed health bill
123 - Resolute Fort Hood soldiers ready for return
119 - McGinn more than doubles his lead over Mallahan
99 - Cutaia says replay handled properly on Austin TD
69 - Josh Smith picks UCLA
69
- For 80-year-old Maple Valley man, hoops aren't just a dream
- Plans call for Triangle to become West Seattle gateway
- Three more fires ignite in Greenwood
- 'Missing' SeaTac man found with new name, in new state
- Pakistani-American cafe, bar owner on verge of being Granite Falls mayor
- Silver Lake restaurant destroyed by fire
- All You Can Eat | Fruit flies: thrill to the kill
- Taste | Ruth Reichl still reigns as queen of America's culinary scene
- Police: DNA from officer's slaying matches suspect
- Book review | Ayn Rand: goddess of the market, gateway to the American right





